Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3334 - Clinical impact of FISH analysis in extramedullary plasmacytomas


09 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Multiple Meyloma


Hyun Ae Jung


Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373


H.A. Jung1, C.H. Maeng2, J.H. Jang3, C.W. Jung3, K. Kim3

Author affiliations

  • 1 Division Of Hematology-oncology, Department Of Medicine, Dongtan Sacred Heart Hospital, 445-907 - Hwanseong-si/KR
  • 2 Division Of Hematology-oncology, Department Of Medicine, Kyoung Hee University school of Medicine, Seoul/KR
  • 3 Division Of Hematology-oncology, Department Of Medicine, Samsung Medical Center, Seoul/KR


Abstract 3334


Extramedullary plasmacytomas (EMPs) is a rare presentation of plasma cell neoplasm and accounts for 7 to 15% of all plasma cell neoplasm. Fluorescence in-situ hybridization (FISH)-detected abnormalities, including del(17p), del(13q), and t(4;14), have been associated with inferior prognosis. However, there are few data about the prognostic significance of cytogenetic abnormalities in multiple myeloma (MM) patients with extramedullary plasmacytoma (EMP). This study aimed the clinical features, FISH data and outcome of patients with EMPs.


The data were collected from 70 patients with EMPs, retrospectively. We excluded skeletal plasmacytomas. The clinic-pathologic variables and treatment outcome retrospectively reviewed.


Seventeen patients had solitary EMPs. Most common site of solitary EMP was nasal cavity and most patients received radiotherapy (n = 7) and surgery (n = 6). A total of 905 patients with newly diagnosed MM were included, and 53 patients (8.7%) had EMPs at diagnosis. Thirty-three patients had conventional FISH data. By conventional cytogenetic analysis and FISH, 35.8% (19/53) and 54.5% (18/33) patients were identified genetic abnormalities, respectively. By comprehensive cytogenetic/FISH approach, the most common genetic aberration was 1q21 amplification and/or 1p32 deletion (42.4%, 14/33), followed by -13 or del (13q) (24.3%, 8/33), del (17p) (15.2%, 5/33), IGH/FGFR3 rearrangement (15%, 2/33) and IGH/CCND1 rearrangement (12%, 2/33). Patients with initial EMPs had significantly worse overall survival compared to those without initial EMPs. Del(13q), and t (4;14) have been associated with inferior prognosis.


In the current study, del(13q), and t (4;14) were associated with worse survival in MM patients with EMP.

Clinical trial identification

Legal entity responsible for the study

Hyun Ae Jung




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.